GI-Map Test Gives New Clinical Insights – Dr David Brady
The GI-Map test can support many aspects of clinical diagnosis and prescribing. In this video, Dr Brady discusses four important dimensions that are revealed in the GI-Map Test: autoimmunity, measuring pancreatic digestive enzymes, the GI-MAP’s primary inflammatory marker test, and measuring for drug-resistant genes.
Autoimmunity: three elements for a ‘perfect storm’
In autoimmunity, we know it’s a perfect storm of factors that come together to create an environment where an autoimmune disease can manifest itself. Those three major elements that need to be there are:
Genetic Susceptibility of the person
An Environmental Antigen
Exposure to some environmental antigen may flare up their immune response. Many times, this is a microbe that would be overgrowing in the gut; most commonly bacteria.
Certain bacteria have certain proteins on them, which the immune system looks at to learn that structure so that they know what to attack, they know what’s the bad guy. Sometimes that structure is very similar to a protein on one of your own tissues and the body can get confused. It’s called molecular mimicry and the presence of that bacteria overgrowing and a genetic susceptibility can actually result in the immune system then inappropriately getting confused and attacking a very specific tissue.
We know specific relationships between certain bacteria, or families or groups of bacteria, and the immune system attacking specific tissues in the body. So there are certain overgrowth patterns associated with different types of autoimmune disease.
Probability Of Leaky Gut
01:24 And then the other final factor is that there are referendums on the test to look at the probability of leaky gut or inflamed mucosal barriers
Things like zonulin, things like calprotectin; and if that’s in play and there’s leaky gut, that’s another risk factor for autoimmunity, so we need to take steps to try to change the health and the integrity of the mucosal barrier.
Pancreatic Elastase-1 Measures Pancreatic Digestive Enzymes
01:53 Pancreatic elastase 1 has been shown over the years in research, primarily out of Germany, to be the best marker to get a referendum on overall output of pancreatic digestive enzymes. Rather than have to test each of the enzymes; like having to test of proteases, amylase, lipase, elastase; it’s been shown in a multitude of studies; it’s very repeatable; that as elastase goes, the rest of them go.
So if you can just look at elastase, you have a pretty good idea of how the pancreas is doing producing all of those different enzymes that we rely on to digest our foods.
02:34 The added benefit of testing elastase is that most digestive enzyme supplements do not contain elastase. So even if they’re taking a digestive enzyme supplement, you can look at the elastase marker and it will not be altered by the fact that they’re taking an exogenous enzyme product because that product will not have elastase in it.
Calprotectin: GI-MAP’s Primary Inflammatory Marker
02:58 The GI-MAP’s main inflammatory marker is faecal calprotectin. Calprotectin is a protein that is produced and found along the GI mucosa and then it is shed into the lumen. It can be found in a stool sample in patients that have inflammation, whether that inflammation is due to an infection or due to some other sort of irritant, such as a food intolerant, like a gluten and gliadin intolerance. Or in many cases, if it’s very, very high it can be a sign, although it’s not a definitive diagnostic marker for colon cancer.
Testing for Drug-Resistant Genes
03:43 Drug-resistant genes are included with the GI-MAP test, specifically in scenarios where a practitioner might want to use a prescriptive agent or a prescriptive antibiotic to treat an infection. So we’re looking throughout the microbiota with a particular eye with H. pylori to resident genes within those bacterial populations, which would render them resistant to specific antibiotic agents.
And if the resistance genes for a specific antibiotic agent are there, they are not the antibiotic you would choose to use clinically because the organism would simply be resistant to it, and you would be actually fostering even more antibiotic resistance because you’re calling the heard to shape it with that specific antibiotic resistance.
So antibiotic resistance is something you would want to intentionally avoid not only because the treatment might not be as efficacious, but you might actually be making things worse.
Source: Live interview with Dr David Brady, December 2018, Sydney Australia
Designs for Health Australia proudly presented the
Learn about the clinical applications and the research behind this new DNA/PCR stool test.
Presented by Dr David Brady, Chief Medical Officer for Diagnostic Solutions Laboratories and Dr Oscar Coetzee, Doctor of Clinical Nutrition and Associate Professor.